New program boosts PrEP adherence in Stimulant-Using men

NCT ID NCT04899024

Completed Prevention Sponsor: Florida International University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a program called PARTI to help gay and bisexual men who use stimulants (like meth or cocaine) take their daily HIV prevention pill (PrEP) consistently. The program combined positive affect skills training with a smartphone-based reward system for taking PrEP. Researchers enrolled 239 men across multiple sites to see if this approach reduced HIV risk by improving medication adherence and reducing risky sex.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: behavioral intervention (PARTI: positive affect skills training plus contingency management)
What this could lead to: If successful, this approach could help high-risk men better adhere to PrEP and reduce new HIV infections.
What could go wrong: This is a completed behavioral study, not a drug trial. Results may not apply to all populations, and adherence improvements may not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Medication Adherence HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREVENTION MEDICATION ADHERENCE STIMULANT USE

Contacts and locations

Locations

University of California, San Francisco

San Francisco, California, 94143, United States
University of Miami Miller School of Medicine

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.